GTC--NVIDIA today announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics. Part of NVIDIA AI Foundations, the new BioNeMo Cloud service offering -- for both AI model training and inference -- accelerates the most time-consuming and costly stages of drug discovery. It enables researchers to fine-tune generative AI applications on their own proprietary data, and to run AI model inference directly in a web browser or through new cloud application programming interfaces (APIs) that easily integrate into existing applications. "The transformative power of generative AI holds enormous promise for the life science and pharmaceutical industries," said Kimberly Powell, vice president of healthcare at NVIDIA. "NVIDIA's long collaboration with pioneers in the field has led to the development of BioNeMo Cloud Service, which is already serving as an AI drug discovery laboratory. It provides pretrained models and allows customization of models with proprietary data that serve every stage of the drug-discovery pipeline, helping researchers identify the right target, design molecules and proteins, and predict their interactions in the body to develop the best drug candidate."

Integration of AI in the biotech industry has brought about a revolution in the healthcare sector. The use of AI in biotech has opened up new avenues for personalized medicine, predictive diagnostics, and cutting-edge research. In this article, we take a look at the top AI-enabled biotech companies leading the charge in the integration of AI and biotechnology. Biotechnology is a branch of biology that uses living organisms, cells, and biological systems to develop new technologies and products. It encompasses a wide range of scientific disciplines, including genetics, molecular biology, microbiology, biochemistry, and chemical engineering, and it has applications in many different fields, such as agriculture, food science, medicine, and environmental protection. In biotechnology, living organisms and biological systems are used to produce and improve products, processes, and technologies.

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to radically improve the lives of patients and industrialize drug discovery. Our team is working to solve some of the hardest, most meaningful problems facing human health today. Come join us in our mission to decode biology to radically improve lives, while doing the most impactful work of your life. This position can be remote or based in Salt Lake City, UT. In this role, you will be at the forefront of reimagining neuroscience drug discovery using Recursion's unique capacity to perform 1 million experiments per week.

As the CEO of one of the top global AI-powered biotechnology companies, I regularly get to see some of the world's most innovative techno parks and biotechnology hubs that are popping up all over the world. Over the past couple of years, I traveled to several such centers in the US, Canada, China, Singapore, and the Middle East. We even established one of our R&D centers at the Hong Kong Science and Technology Park. All of these centers have their advantages and disadvantages that often go in line with the government policies and I will try to cover some of these centers in my future posts and make a comparison. So far, some of the most impressive biotechnology hubs are in China and in Singapore.

It is concentrating on the development of new biopharmaceuticals using antibody technology, RNA, and proteins. The goal is to develop innovative biopharmaceuticals based on biotechnology to solve unmet demand for diseases for which there is no treatment. Amgen Korea announced on the 26th that from July last year to the beginning of this year, it was working with three companies with promising technologies to develop new drugs and focusing on various research and development cooperation based on biotechnology. According to the contents of the cooperation with the companies Amgen Korea has cooperated with, it has signed a research alliance with Generate Biomedicines to develop protein therapeutics using a machine learning-based platform, and cooperated with Arrakis Therapeutics to develop small molecules that degrade RNA. Arachis Therapeutics Selectively Destroys RNA... Started Developing'Small Molecular Therapeutics' On January 11, this year, Amgen and Arakis Therapeutics signed an agreement to develop new'RNA-degrading small molecule drugs'.

Connecta Therapeutics, a biotechnology company that specialises in the discovery and development of new treatments for unmet central nervous system (CNS) needs, has been granted €247,577 in funding through the Neotec programme, managed by the Spanish Ministry of Science and Innovation Centre for the Development of Industrial Technology (CDTI), in its 2021 call for projects. This funding will go towards advancing Connecta's business plan, by exploring new therapeutic indications in the CNS field and launching the paediatric plan for its pre-clinical asset CTH120. CTH120 is a neuroplasticity modulator, designed using artificial intelligence tehniques, that has been shown to improve cognitive abilities and reverse social interaction impairments observed in neurodevelopmental disorders. In 2022, Connecta Therapeutics will start Phase I clinical trials for CTH120 in Fragile X Syndrome (FXS), for which it has received the orphan drug designation from the European Medicines Agency. Dr Josep Prous, jr, co-founder and Chief Scientific Officer at Connecta Therapeutics, stated: "We're very satisfied to become part of the prestigious list of start-up companies to receive Neotec funding. This recognition validates and reinforces our development plan for Fragile X Syndrome and will allow us to explore CTH120's potential benefit in other CNS conditions."

OpenBench, Inc., an emerging leader in AI-enabled small molecule discovery, entered into an agreement with HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, to use the OpenBench virtual screening platform to identify novel, potent inhibitors of an undisclosed rare disease target. Under the terms of the agreement, OpenBench will receive payment for successful identification and experimental confirmation of novel chemotypes that meet HemoShear's potency and developability criteria. Financial terms were not disclosed. "We are excited to support HemoShear's efforts to identify clinically relevant therapeutic candidates for a rare disease with significant unmet patient need," said OpenBench CTO James Yoder. "We feel confident that the OpenBench technology will pair nicely with the HemoShear REVEAL-Tx platform to help identify potent, developable hits and optimize the likelihood of success for this HemoShear discovery program."

As previously discussed in this blog post, Artificial Intelligence has made leaps and bounds in its capabilities over the past decade, to the point that this once novel technology has become an integral part of any biotechnology company. With differentiation in AI itself dwindling, industries are being rebuilt around the application of AI. One such prominent space is biotechnology, which today is amongst the largest global industries at an estimated value of $753B. It is expected to grow to nearly $2.5T by 2028. To keep up with this growth, new AI companies and products are being created to uncover the most relevant data points from this enormous data haystack.

IMAGE: Covax-19 is an Australian-developed COVID-19 vaccine developed with the help of computational and artificial intelligence (AI)-based technologies. Given the global urgency of the COVID-19 pandemic, Microsoft's AI for Health program has stepped in to support the development and potential deployment of Vaxine's COVAX-19 vaccine with a philanthropic grant. Vaxine Pty Ltd, a biotechnology company based in South Australia, uses computational and artificial intelligence (AI)-based technologies to accelerate pandemic vaccine and drug development with the aim to reduce drug development processes that normally take decades down to just weeks. The Microsoft AI and Azure cloud capabilities will help the company accelerate clinical testing of its COVAX-19 vaccine. "Large international Phase 3 vaccine trials are extraordinarily complex and generate vast amounts of data that needs to be efficiently processed", says Vaxine Research Director, Flinders University Professor Nikolai Petrovsky.

PALO ALTO, CA – September 16, 2019 – Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical need, today announced that data on AU-409, the company's lead drug candidate being developed for the treatment of hepatocellular carcinoma (HCC), will be presented at the 13th Annual Conference of the International Liver Cancer Association (ILCA). The study results will be featured in an oral presentation at the conference, which is being held September 20-22, 2019, in Chicago, IL. AU-409 is Auransa's lead drug candidate and was generated leveraging the company's proprietary AI-driven SMarTR Engine. The SMarTR Engine tackles disease heterogeneity and leverages gene expression profiles to predict responder patient populations, as well as compounds that might be effective against those patient populations. Auransa designed AU-409 to combine three essential features: DNA binding activity, antitumor activity in vitro and in vivo, and good oral bioavailability.